Standards & guidance

Filter Standards and Guidance documents

Page 3 of 13

FSRH Guideline-related resources: Intrauterine Contraception (March 2023)

20 April 2023

Additional resources supporting FSRH Guideline: Intrauterine Contraception

This resource is available to members/candidates of FSRH.

This document is up-to-date

FSRH CEU Guidance: Intrauterine Contraception Quick Reference Summary (April 2023)

18 April 2023

This summary has been written as a quick reference guide to help busy clinicians to give clear, safe advice on intrauterine contraception. Please refer to the full 2023 FSRH Intrauterine Contraception Clinical Guideline for further information and evidence for this advice.

This resource is available to members/candidates of FSRH.

This document is up-to-date

FSRH CEU Statement: New manufacturer/MHRA advice regarding nomegestrol acetate – how does this affect prescribing of Zoely®? (April 2023)

13 April 2023

Theramex, in agreement with the MHRA, has issued a direct healthcare professional communications (DHPC) letter relating to prescribing of Zoely®, a combined oral contraceptive containing estradiol in combination with 2.5mg of the progestogen nomegestrol acetate (NOMAC). The guidance is a response to evidence indicating an association between use of preparations containing nomegestrol acetate at higher doses than in Zoely (3.75mg-5mg) and increased risk of intracranial meningioma. There is not evidence relating directly to use of Zoely itself.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH response to new study using a mathematical model to inform dose and regimen of exogenous hormones (April 2023)

13 April 2023

A new mathematical model suggests that effective suppression of ovulation for contraception could be achieved using lower doses of progestogen and estrogen than those currently used in hormonal contraceptives. A paper published today in PLOS Computational Biology describes the model and its findings. The authors highlight that lower exposure to exogenous hormones could reduce associated health risks and side effects. The model could be used to inform dose and regimen of exogenous hormones to be investigated by future clinical trials seeking to find new options for safe, effective and acceptable contraception. Clinical trials would be required to investigate what outcomes, with such regimens, were found in practice.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH New Product Review: Intrauterine Ball (IUBTM) Ballerine® MIDI (February 2019) (Updated April 2023)

11 April 2023

Manufactured by OCON Medical Ltd, the Intrauterine Ball (IUB™) SCu300B MIDI is a copper intrauterine device (Cu-IUD) comprised of copper beads with a total exposed copper surface of 300mm² strung on a flexible Nitinol (nickel/titanium alloy), PET-coated frame. Once the IUB is released from the 3.2mm diameter insertion tube into the uterus it coils into a spherical shape measuring 15mm in diameter. Download the product review in full here.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU Guidance: Switching or Starting Methods of Contraception (April 2023)

03 April 2023

This quick guide advises on effective starting or switching between contraceptive methods to reduce the risk of unplanned pregnancy. It summarises information from existing FSRH guidance documents. This guide should be used in conjunction with clinical judgment in individual situations. Published April 2023. 

This resource is available to members/candidates of FSRH.

This document is up-to-date

FSRH Guideline-related CPD Q&A: Intrauterine Contraception (March 2023)

31 March 2023

Login to view this document. 1 CPD credit can be claimed for reading the guidance. 1 CPD credit can be claimed for answering the questions.

This resource is available to members/candidates of FSRH.

This document is up-to-date

FSRH Response to new study on use of CHC and POC and breast cancer risk (March 2023)

22 March 2023

This statement is a response to a new observational study by Fitzpatrick et al. (March 2023) which investigated the association between current or recent use of combined oral and progestogen-only hormonal contraception and breast cancer risk.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU Guidance: Drug Interactions Between HIV Antiretroviral Therapy (ART) and Contraception (February 2023)

07 February 2023

This FSRH Guidance provides key information and good practice points for health professionals on drug-drug interactions (DDIs) between HIV antiretroviral therapy (ART) and contraception to facilitate the prescription of safe and effective contraception to people living with HIV and on ART.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date